• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PGL
Click for more information
0.00% 85.0¢

PROSPA GROUP LIMITED. - Announcements

Currently unlisted. Proposed listing date: APPLICATION WITHDRAWN watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
PGL ASX Notice - Update on Admission & Commencement of QuotationPRICE SENSITIVE06/06/18
PGL ASX Market Release - Admission and Commencement of QuotationPRICE SENSITIVE05/06/18
PGL Company Update29/01/16
PGL Appendix 3B - Acquisition of TBG Inc29/01/16
PGL Lapse of Unlisted Options Under ESOP29/01/16
PGL Change of Company Name - TBG Diagnostics Limited14/12/15
PGL Progen successfully raises $12.72 million under Offer11/12/15
PGL Changes to Board of Directors09/12/15
PGL Suspension from Official QuotationPRICE SENSITIVE07/12/15
PGL Results of General Meeting07/12/15
PGL Results of AGM07/12/15
PGL Trading HaltPRICE SENSITIVE07/12/15
PGL Minimum Subscription of $10m Reached03/12/15
PGL Receipt of R&D Tax Incentive RefundPRICE SENSITIVE26/11/15
PGL Lodgement of Supplementary Prospectus24/11/15
PGL Extension of Exposure Period18/11/15
PGL Amended Announcement - Lodgement of Prospectus and App 3B11/11/15
PGL Lodgement of Prospectus and Appendix 3BPRICE SENSITIVE11/11/15
PGL 2015 AGM & General Meeting Documentation04/11/15
PGL 2015 Form 20-F Filed with the US SEC02/11/15
PGL TBG Acquisition - Updated Independent Expert's Report02/11/15
PGL Update - TBG Acquisition & Dates of AGM and General Meeting02/11/15
PGL TBG Acquisition - Independent Expert's ReportPRICE SENSITIVE19/10/15
PGL Progen to Proceed with Strategic Acquisition of TBG Inc.PRICE SENSITIVE16/10/15
PGL Corporate Governance Statement & Appendix 4G30/09/15
PGL Annual Report to shareholders30/09/15
PGL Preliminary Final ReportPRICE SENSITIVE24/08/15
PGL Initial & Final Directors' Interest Notices06/08/15
PGL Proposed Acquisition of TBG Inc and Strategic ReviewPRICE SENSITIVE01/05/15
PGL Lapse of Unlisted Options Under ESOP29/04/15
PGL Director Appointment/Resignation16/03/15
PGL Half Yearly Report & AccountsPRICE SENSITIVE27/02/15
PGL Receipt of R&D Tax Incentive RefundPRICE SENSITIVE17/02/15
PGL PI-88 Clinical Trial UpdatePRICE SENSITIVE28/01/15
PGL PG545 Phase 1 Trial Successfully Completes Third CohortPRICE SENSITIVE19/12/14
PGL Change of Director's Interest Notice - Mr Jitto Arulampalam20/11/14
PGL Change of Director's Interest Notice - Mr Heng Hsin Tang20/11/14
PGL Change of Director's Interest Notice - Dr Hongjen Chang20/11/14
PGL Issue of Unlisted Options to Contractors & Appendix 3B20/11/14
PGL Issue of Unlisted Options to Directors & Appendix 3B20/11/14
PGL Notice of Allowance of Canada Patent for PG545PRICE SENSITIVE14/11/14
PGL 2014 Form 20-F Filed with the US SEC13/11/14
PGL Results of Meeting07/11/14
PGL Chairman's Address to Shareholders07/11/14
PGL Notice of Annual General Meeting/Proxy Form07/10/14
PGL 2014 Annual Report29/09/14
PGL PG545 Phase 1 Clinical Trial UpdatePRICE SENSITIVE22/09/14
PGL Preliminary Final ReportPRICE SENSITIVE26/08/14
PGL Update to Interim Phase III Results for PI-88PRICE SENSITIVE29/07/14
PGL Interim Phase III Results for PI-88PRICE SENSITIVE28/07/14
PGL EPO to Grant Sulfated Oligosaccharide Derivatives PatentPRICE SENSITIVE21/07/14
PGL Medigen Schedules PI-88 Interim Patient Analysis in July09/07/14
PGLChange of Head Office Address28/05/14
PGLChange of Director's Interest Notice19/05/14
PGLPG545 Phase 1 Clinical Trial UpdatePRICE SENSITIVE15/05/14
PGLChanges to Management & Corporate Office AddressPRICE SENSITIVE14/05/14
PGLMedigen Expects PI-88 Interim Patient Data in May 2014PRICE SENSITIVE08/05/14
PGLMedigen Engages PharmaSynth to Manufacture PI-88PRICE SENSITIVE29/04/14
PGLNotice of Allowance of US patent for PG545PRICE SENSITIVE28/04/14
PGLPG545 Data Presented at AACR ConferencePRICE SENSITIVE09/04/14
PGLIssue of Unlisted Options under ESOP02/04/14
PGLResponse to ASX Price QueryPRICE SENSITIVE17/03/14
PGLChange of Director's Interest Notice13/03/14
PGLHalf Yearly Report and AccountsPRICE SENSITIVE27/02/14
PGLPG545 Data Presented at Lorne Cancer Conference13/02/14
PGLReceipt of R& D Tax Incentive Refund31/01/14
PGLResponse to ASX Price QueryPRICE SENSITIVE30/01/14
PGLPATRON Trial Completes Patient RecruitmentPRICE SENSITIVE30/12/13
PGLChange of Director's Interest Notice20/12/13
PGLR&D Tax Incentive RefundPRICE SENSITIVE17/12/13
PGL2013 Form 20-F/A Filed with the US SEC13/12/13
PGLChange of Director's Interest Notice06/12/13
PGLBeta Therapeutics Assignment AgreementPRICE SENSITIVE03/12/13
PGLInitial Director's Interest Notice - Hongjen Chang02/12/13
PGLFinal Director's Interest Notice - Stuart James29/11/13
PGLAppointment of Director and Chair29/11/13
PGLResults of Annual General Meeting28/11/13
PGL2013 Annual General Meeting AddressPRICE SENSITIVE28/11/13
PGLChange to Board of Directors27/11/13
PGL2013 Form 20-F Filed with the US SEC01/11/13
PGLPG545 Phase 1 Cancer Trial UpdatePRICE SENSITIVE29/10/13
PGLNotice of Annual General Meeting/Proxy Form25/10/13
PGLChange to Acting Managing Director's Terms of EmploymentPRICE SENSITIVE21/10/13
PGLAppendix 3B - Issue of Unlisted Options03/10/13
PGLAnnual Report to shareholders27/09/13
PGLPreliminary Final ReportPRICE SENSITIVE27/08/13
PGLUpdate on PG545 Preclinical ProgramPRICE SENSITIVE22/08/13
PGLPI-88 Phase III Update22/07/13
PGLFinal Director's Interest Notice15/07/13
PGLInitial Director's Interest Notice15/07/13
PGLBoard and Senior Management ChangesPRICE SENSITIVE12/07/13
PGLPG545 Preclinical Data Published in Molecular Cancer Therape09/07/13
PGLCeasing to be a substantial holder05/06/13
PGLCeasing to be a substantial holder30/05/13
PGLChange in substantial holding29/05/13
PGLBecoming a substantial holder29/05/13
PGLShare Placement - Notice under Section 708A(5)(e)29/05/13
PGLShare Placement & Appendix 3BPRICE SENSITIVE27/05/13
PGLChange in substantial holding24/05/13
PGLChange of Director's Interest Notice22/05/13
PGL ASX Notice - Update on Admission & Commencement of Quotation
06/06/18PRICE SENSITIVE
PGL ASX Market Release - Admission and Commencement of Quotation
05/06/18PRICE SENSITIVE
PGL Company Update
29/01/16
PGL Appendix 3B - Acquisition of TBG Inc
29/01/16
PGL Lapse of Unlisted Options Under ESOP
29/01/16
PGL Change of Company Name - TBG Diagnostics Limited
14/12/15
PGL Progen successfully raises $12.72 million under Offer
11/12/15
PGL Changes to Board of Directors
09/12/15
PGL Suspension from Official Quotation
07/12/15PRICE SENSITIVE
PGL Results of General Meeting
07/12/15
PGL Results of AGM
07/12/15
PGL Trading Halt
07/12/15PRICE SENSITIVE
PGL Minimum Subscription of $10m Reached
03/12/15
PGL Receipt of R&D Tax Incentive Refund
26/11/15PRICE SENSITIVE
PGL Lodgement of Supplementary Prospectus
24/11/15
PGL Extension of Exposure Period
18/11/15
PGL Amended Announcement - Lodgement of Prospectus and App 3B
11/11/15
PGL Lodgement of Prospectus and Appendix 3B
11/11/15PRICE SENSITIVE
PGL 2015 AGM & General Meeting Documentation
04/11/15
PGL 2015 Form 20-F Filed with the US SEC
02/11/15
PGL TBG Acquisition - Updated Independent Expert's Report
02/11/15
PGL Update - TBG Acquisition & Dates of AGM and General Meeting
02/11/15
PGL TBG Acquisition - Independent Expert's Report
19/10/15PRICE SENSITIVE
PGL Progen to Proceed with Strategic Acquisition of TBG Inc.
16/10/15PRICE SENSITIVE
PGL Corporate Governance Statement & Appendix 4G
30/09/15
PGL Annual Report to shareholders
30/09/15
PGL Preliminary Final Report
24/08/15PRICE SENSITIVE
PGL Initial & Final Directors' Interest Notices
06/08/15
PGL Proposed Acquisition of TBG Inc and Strategic Review
01/05/15PRICE SENSITIVE
PGL Lapse of Unlisted Options Under ESOP
29/04/15
PGL Director Appointment/Resignation
16/03/15
PGL Half Yearly Report & Accounts
27/02/15PRICE SENSITIVE
PGL Receipt of R&D Tax Incentive Refund
17/02/15PRICE SENSITIVE
PGL PI-88 Clinical Trial Update
28/01/15PRICE SENSITIVE
PGL PG545 Phase 1 Trial Successfully Completes Third Cohort
19/12/14PRICE SENSITIVE
PGL Change of Director's Interest Notice - Mr Jitto Arulampalam
20/11/14
PGL Change of Director's Interest Notice - Mr Heng Hsin Tang
20/11/14
PGL Change of Director's Interest Notice - Dr Hongjen Chang
20/11/14
PGL Issue of Unlisted Options to Contractors & Appendix 3B
20/11/14
PGL Issue of Unlisted Options to Directors & Appendix 3B
20/11/14
PGL Notice of Allowance of Canada Patent for PG545
14/11/14PRICE SENSITIVE
PGL 2014 Form 20-F Filed with the US SEC
13/11/14
PGL Results of Meeting
07/11/14
PGL Chairman's Address to Shareholders
07/11/14
PGL Notice of Annual General Meeting/Proxy Form
07/10/14
PGL 2014 Annual Report
29/09/14
PGL PG545 Phase 1 Clinical Trial Update
22/09/14PRICE SENSITIVE
PGL Preliminary Final Report
26/08/14PRICE SENSITIVE
PGL Update to Interim Phase III Results for PI-88
29/07/14PRICE SENSITIVE
PGL Interim Phase III Results for PI-88
28/07/14PRICE SENSITIVE
PGL EPO to Grant Sulfated Oligosaccharide Derivatives Patent
21/07/14PRICE SENSITIVE
PGL Medigen Schedules PI-88 Interim Patient Analysis in July
09/07/14
PGLChange of Head Office Address
28/05/14
PGLChange of Director's Interest Notice
19/05/14
PGLPG545 Phase 1 Clinical Trial Update
15/05/14PRICE SENSITIVE
PGLChanges to Management & Corporate Office Address
14/05/14PRICE SENSITIVE
PGLMedigen Expects PI-88 Interim Patient Data in May 2014
08/05/14PRICE SENSITIVE
PGLMedigen Engages PharmaSynth to Manufacture PI-88
29/04/14PRICE SENSITIVE
PGLNotice of Allowance of US patent for PG545
28/04/14PRICE SENSITIVE
PGLPG545 Data Presented at AACR Conference
09/04/14PRICE SENSITIVE
PGLIssue of Unlisted Options under ESOP
02/04/14
PGLResponse to ASX Price Query
17/03/14PRICE SENSITIVE
PGLChange of Director's Interest Notice
13/03/14
PGLHalf Yearly Report and Accounts
27/02/14PRICE SENSITIVE
PGLPG545 Data Presented at Lorne Cancer Conference
13/02/14
PGLReceipt of R& D Tax Incentive Refund
31/01/14
PGLResponse to ASX Price Query
30/01/14PRICE SENSITIVE
PGLPATRON Trial Completes Patient Recruitment
30/12/13PRICE SENSITIVE
PGLChange of Director's Interest Notice
20/12/13
PGLR&D Tax Incentive Refund
17/12/13PRICE SENSITIVE
PGL2013 Form 20-F/A Filed with the US SEC
13/12/13
PGLChange of Director's Interest Notice
06/12/13
PGLBeta Therapeutics Assignment Agreement
03/12/13PRICE SENSITIVE
PGLInitial Director's Interest Notice - Hongjen Chang
02/12/13
PGLFinal Director's Interest Notice - Stuart James
29/11/13
PGLAppointment of Director and Chair
29/11/13
PGLResults of Annual General Meeting
28/11/13
PGL2013 Annual General Meeting Address
28/11/13PRICE SENSITIVE
PGLChange to Board of Directors
27/11/13
PGL2013 Form 20-F Filed with the US SEC
01/11/13
PGLPG545 Phase 1 Cancer Trial Update
29/10/13PRICE SENSITIVE
PGLNotice of Annual General Meeting/Proxy Form
25/10/13
PGLChange to Acting Managing Director's Terms of Employment
21/10/13PRICE SENSITIVE
PGLAppendix 3B - Issue of Unlisted Options
03/10/13
PGLAnnual Report to shareholders
27/09/13
PGLPreliminary Final Report
27/08/13PRICE SENSITIVE
PGLUpdate on PG545 Preclinical Program
22/08/13PRICE SENSITIVE
PGLPI-88 Phase III Update
22/07/13
PGLFinal Director's Interest Notice
15/07/13
PGLInitial Director's Interest Notice
15/07/13
PGLBoard and Senior Management Changes
12/07/13PRICE SENSITIVE
PGLPG545 Preclinical Data Published in Molecular Cancer Therape
09/07/13
PGLCeasing to be a substantial holder
05/06/13
PGLCeasing to be a substantial holder
30/05/13
PGLChange in substantial holding
29/05/13
PGLBecoming a substantial holder
29/05/13
PGLShare Placement - Notice under Section 708A(5)(e)
29/05/13
PGLShare Placement & Appendix 3B
27/05/13PRICE SENSITIVE
PGLChange in substantial holding
24/05/13
PGLChange of Director's Interest Notice
22/05/13
refresh Created with Sketch. REFRESH
 

Top Stories

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
HotCopper Highlights: Your most watched stocks for Week 46, 2024 What you - HotCopper users - were most interested in viewing and discussing this week (Week 46 of the year!)
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.